Organigram’s major shareholder is the global tobacco and nicotine giant British American Tobacco (BAT), which holds a substantial strategic equity stake of approximately 30% in the company. The remaining ownership structure is distributed among various institutional investment funds, asset management firms (such as Tidal Investments and Renaissance Technologies), and a vast base of public retail shareholders trading on the NASDAQ and Toronto Stock Exchange.